316 related articles for article (PubMed ID: 12881704)
41. A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect.
Crook T; Parker GA; Rozycka M; Crossland S; Allday MJ
Oncogene; 1998 Mar; 16(11):1429-41. PubMed ID: 9525742
[TBL] [Abstract][Full Text] [Related]
42. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
43. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
Bae I; Fan S; Bhatia K; Kohn KW; Fornace AJ; O'Connor PM
Cancer Res; 1995 Jun; 55(11):2387-93. PubMed ID: 7757991
[TBL] [Abstract][Full Text] [Related]
44. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
45. [Activator of metastasis in cancer cells, Mst1/S100A4 protein binds to tumor suppressor protein p53].
Grigorian M; Lukanidin E
Genetika; 2003 Jul; 39(7):900-8. PubMed ID: 12942774
[TBL] [Abstract][Full Text] [Related]
46. Cardiac transcription factor Nkx2.5 interacts with p53 and modulates its activity.
Kojic S; Nestorovic A; Rakicevic L; Protic O; Jasnic-Savovic J; Faulkner G; Radojkovic D
Arch Biochem Biophys; 2015 Mar; 569():45-53. PubMed ID: 25677450
[TBL] [Abstract][Full Text] [Related]
47. Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1.
Burch LR; Scott M; Pohler E; Meek D; Hupp T
J Mol Biol; 2004 Mar; 337(1):115-28. PubMed ID: 15001356
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
Park US; Park SK; Lee YI; Park JG; Lee YI
Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
[TBL] [Abstract][Full Text] [Related]
49. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
50. A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization.
Xu GW; Mawji IA; Macrae CJ; Koch CA; Datti A; Wrana JL; Dennis JW; Schimmer AD
Apoptosis; 2008 Mar; 13(3):413-22. PubMed ID: 18181020
[TBL] [Abstract][Full Text] [Related]
51. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
[TBL] [Abstract][Full Text] [Related]
52. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
Vassilev LT; Vu BT; Graves B; Carvajal D; Podlaski F; Filipovic Z; Kong N; Kammlott U; Lukacs C; Klein C; Fotouhi N; Liu EA
Science; 2004 Feb; 303(5659):844-8. PubMed ID: 14704432
[TBL] [Abstract][Full Text] [Related]
53. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality.
Montes de Oca Luna R; Amelse LL; Chavez-Reyes A; Evans SC; Brugarolas J; Jacks T; Lozano G
Nat Genet; 1997 Aug; 16(4):336-7. PubMed ID: 9241268
[No Abstract] [Full Text] [Related]
54. Functional interplay between p53 and E2F through co-activator p300.
Lee CW; Sørensen TS; Shikama N; La Thangue NB
Oncogene; 1998 May; 16(21):2695-710. PubMed ID: 9652736
[TBL] [Abstract][Full Text] [Related]
55. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains.
Venot C; Maratrat M; Sierra V; Conseiller E; Debussche L
Oncogene; 1999 Apr; 18(14):2405-10. PubMed ID: 10327062
[TBL] [Abstract][Full Text] [Related]
56. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
57. How many mutant p53 molecules are needed to inactivate a tetramer?
Chan WM; Siu WY; Lau A; Poon RY
Mol Cell Biol; 2004 Apr; 24(8):3536-51. PubMed ID: 15060172
[TBL] [Abstract][Full Text] [Related]
58. The contribution of the RING finger domain of MDM2 to cell cycle progression.
Argentini M; Barboule N; Wasylyk B
Oncogene; 2000 Aug; 19(34):3849-57. PubMed ID: 10951578
[TBL] [Abstract][Full Text] [Related]
59. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21.
Jabbur JR; Tabor AD; Cheng X; Wang H; Uesugi M; Lozano G; Zhang W
Oncogene; 2002 Oct; 21(46):7100-13. PubMed ID: 12370832
[TBL] [Abstract][Full Text] [Related]
60. Constitutive and DNA damage inducible activation of pig3 and MDM2 genes by tumor-derived p53 mutant C277Y.
Pospísilová S; Siligan C; Ban J; Jug G; Kovar H
Mol Cancer Res; 2004 May; 2(5):296-304. PubMed ID: 15192123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
